Skip to main content
. 2017 May 25;5(1):28–36. doi: 10.1093/nop/npx008

Fig. 4.

Fig. 4

MTV following 4 weeks of bevacizumab shown as a percent of baseline MTV for each lesion measured in the 6 patients.